Unlike the existing GLP-1 agonists such as Wegovy, Ozempic and Zepbound, which require injections, GSBR-1290 offers the convenience of oral administration.
To date, there have been no reported cases associating GLP-1 agonists with rhabdomyolysis, making this revelation a significant milestone in medical research.
Following the initiation of Ozempic, people previously reliant on CPAP are seeing remarkable improvements in their symptoms of sleep apnea.
Senator Bernie Sanders is spearheading a crucial hearing that will delve into the alarming disparity in the pricing of diabetes drugs between the United States and other countries.
The first evidence of semaglutide’s specific efficacy in alleviating symptoms of Alcohol Use Disorder (AUD) has been published in The Journal of Clinical Psychiatry.
Amgen and Viking are developing obesity medications that show promise in early trials, with Amgen’s drug demonstrating a 14.5% weight loss over 12 weeks and Viking’s achieving an 8% reduction over 28 days.
Pfizer has decided to halt the advancement of danuglipron following a challenging Phase 2b clinical trial, primarily the high incidence of adverse side effects.
The European Medicines Agency (EMA) is scrutinizing of Ozempic and Wegovy for possible links to suicidal thoughts. The investigation was spurred by reports from the Icelandic Medicines Agency and EudraVigilance.
A recent study published in The American Journal of Gastroenterology has revealed a significant association between GLP-1RAs and lower quality of bowel prep for colonoscopies.
While GLP-1 agonists are known for their effective weight loss results, they come with significant drawbacks, including loss of lean muscle mass. Taldefgrobep alfa, a myostatin inhibitor licensed from Bristol Myers Squibb, stands apart by targeting not just fat loss but also muscle preservation.
